Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive bladder cancer (MIBC), given in combination with platinum chemotherapy ...

OPEN The FTSE 100 was expected to open 19.9 points lower on Friday after wrapping up the previous session 0.55% higher at 8,823.20.

Imfinzi claimed an accelerated approval from the FDA in 2017 for advanced-stage bladder cancer, but that was withdrawn in 2021 after it failed a confirmatory trial.

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that Imfinzi (durvalumab) has been approved in the European Union for the treatment of adult patients with resectable ...